BiDil Approval In Blacks Is Step Toward Personalized Medicine, FDA Says
Executive Summary
The approval of NitroMed's BiDil for treatment of heart failure in self-identified blacks is a step in the direction of drugs based on patient characteristics
You may also be interested in...
Personalized Medicine Is Closer Than You Think, FDA’s Throckmorton Says
Personalized medicine should be adopted as a prospective strategy in drug development rather than primarily serving as a tool to salvage failing drug candidates, participants at FDA's Science Forum suggested
Personalized Medicine Is Closer Than You Think, FDA’s Throckmorton Says
Personalized medicine should be adopted as a prospective strategy in drug development rather than primarily serving as a tool to salvage failing drug candidates, participants at FDA's Science Forum suggested
NitroMed/NAACP alliance
NitroMed provides a $1.5 mil. grant to the National Association for the Advancement of Colored People to develop "health advocacy initiatives towards equal access to quality healthcare," the firm announces Dec. 14. Among other initiatives, the grant will support the development of a "consensus paper on the state of African American healthcare and the impact of Medicare" and an Advocacy Action Plan for the NAACP National Health Leadership Committee. NitroMed markets BiDil (isosorbide dinitrate/hydralazine), which was approved in June for treatment of heart failure in self-identified black patients, and is the first therapy indicated for a specific ethnic population (1"The Pink Sheet" June 27, 2005, p. 5)...